^ abcLemini C, Rubio-Póo C, Silva G, García-Mondragón J, Zavala E, Mendoza-Patiño N, Castro D, Cruz-Almanza R, Mandoki JJ (1993). "Anticoagulant and estrogenic effects of two new 17 beta-aminoestrogens, butolame [17 beta-(4-hydroxy-1-butylamino)-1,3,5(10)-estratrien-3-ol] and pentolame [17 beta-(5-hydroxy-1-pentylamino)-1,3,5(10)-estratrien-3-ol]". Steroids. 58 (10): 457–61. doi:10.1016/0039-128x(93)90002-5. PMID8256254. S2CID54381037.
^ abcdGonzález G, Alvarado-Vasquez N, Fernández-G JM, Cruz-Robles D, Del Valle L, Pinzón E, Torres I, Rodriguez E, Zapata E, Gómez-Vidales V, Montaño LF, de la Peña A (2010). "The antithrombotic effect of the aminoestrogen prolame (N-(3-hydroxy-1,3,5(10)-estratrien-17B-YL)-3-hydroxypropylamine) is linked to an increase in nitric oxide production by platelets and endothelial cells". Atherosclerosis. 208 (1): 62–8. doi:10.1016/j.atherosclerosis.2009.06.017. PMID19615684.
^Lemini C, Rubio-Póo C, Franco Y, Jaimez R, Avila ME, Medina M, Lemus AE (2013). "In vivo profile of the anticoagulant effect of 17ß-amino-1,3,5(10)estratrien-3-ol". Eur. J. Pharmacol. 700 (1–3): 210–6. doi:10.1016/j.ejphar.2012.12.030. PMID23305838.
^Rubio-Póo C, Lemini C, Silva G, García-Mondragón J, Zavala E, Castro D, Mendoza-Patiño N, Mandoki JJ (1993). "Comparison of the time course of anticoagulant and estrogenic effects of prolame, butolame, pentolame and hexolame, a homologous series of 17 beta-amino estrogens". Proc. West. Pharmacol. Soc. 36: 143–7. PMID8378368.